Foghorn’s AML/MDS Program Likely Still A Go Despite Partial Hold
Executive Summary
The company’s Phase I study of FHD-286 had a patient death due to differentiation syndrome, but that’s a known adverse event in multiple approved AML drugs.
You may also be interested in...
Lilly Furthers Precision Cancer Ambitions With Foghorn Collaboration
Building on its Loxo Oncology unit, Lilly teams with Foghorn to target cancers caused by BRG1 mutations, about 5% of all tumors, including 10% of NSCLC patients. Merck & Co. teamed up with Foghorn in 2020.
Agios Sells Cancer Portfolio To Servier To Focus On Genetic Diseases
Agios’ cellular metabolism expertise first delivered cancer drugs but sees greater opportunity in genetically defined diseases. CEO Jackie Fouse talked to Scrip about the business strategy.
Merck To Pay Up To $425m For Foghorn’s Gene Regulation Therapies
US major continues its expansion in oncology with an early stage deal with Flagship Pioneering protegés.